Clinical Trials in Germany

• An Open-Label Extension to Study the Long-Term Effect of Dexpramipexole in Participants with Severe Eosinophilic Asthma (EXHALE-5) Under evaluation
  2024-510810-33-00 Phase III Severe eosinophilic asthma Areteia Therapeutics Inc.
• Phase 3 Study of ALXN1850 in Pediatric Participants with HPP Previously Treated with Asfotase Alfa Revoked
  2023-505674-15-00 Phase III Hypophosphatasia Alexion Pharmaceuticals Inc.
• A Parallel-group (2-Arm), Randomized, Double-blind, 12-week Trial to Evaluate the Efficacy and Safety of MC2-25 Cream and MC2-25 Vehicle in… Not authorised
  2022-500044-38-00 Phase II Chronic Kidney Disease associated Pruritus Mc2 Therapeutics Limited
• A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/… Not authorised
  2022-500410-26-00 Phase III Cystic Fibrosis University Medical Center Utrecht
• ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Not authorised
  2022-500535-36-00 Phase III Moderately to severely active ulcerative colitis Abivax
• ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Not authorised
  2022-500536-11-00 Phase III Moderately to severely active ulcerative colitis Abivax
• ABTECT-Maintenance – ABX464 Treatment Evaluation for ulcerative Colitis Therapy Not authorised
  2022-500537-84-00 Phase III Moderately to severely active ulcerative colitis Abivax
• A phase II study evaluating the efficacy and safety of IMetelstat in Patients with HR myElodysplastic SyndromeS or AML failing HMA-based the… Not authorised
  2022-500721-32-00 Phase II AML and MDS patients failing or being refractory to hypometh… Gcp-Service International West GmbH
• A Randomized, Placebo-controlled, Double-blind, Parallel group, 6 Month Study to Evaluate the Safety, Tolerability, and Potential Efficacy o… Not authorised
  2022-500828-30-00 Phase II Early Alzheimer´s Disease Cyclo Therapeutics Inc.
• An European multinational study of a personalized approach of human albumin administration in patients with cirrhosis of the liver and compl… Not authorised
  2022-501006-34-00 Phase III Liver cirrhosis European Foundation For The Study Of Chronic Liver Failure; Odense University Ho…
• Phase2, double-blind, randomized, placebo-controlled, multicentre study to evaluation the safety, efficacy, and pharmacokinetics of TAK-242 … Not authorised
  2022-501026-37-00 Phase II ACLF is a syndrome that occurs in patients with chronic live… Alpha Bioresearch S.L.; Yaqrit Limited
• A 3-month, phase 2, single-blind, randomised, no-treatment controlled study assessing efficacy and safety of Renaparin® for improvement of k… Not authorised
  2022-501389-23-00 Phase II end-stage renal disease or otherwise an insufficient kidney … Corline Biomedical AB
• Clinical trial of MK-7648A in adults and children with skin cancer Not authorised
  2022-501417-31-00 Phase III High-risk Resected Melanoma Merck Sharp & Dohme LLC
• An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma Not authorised
  2022-501463-40-00 Phase III Locally Advanced or Metastatic Cholangiocarcinoma Servier Affaires Medicales
• Phase 3 Study Assessing Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit) Not authorised
  2022-501535-16-00 Phase III Atopic Dermatitis (AD) Amgen Inc.
• A Study to Assess if BIIB080 Can Change Clinical Dementia Rating-Sum of Boxes Scores, and BIIB080 Safety and Tolerability When Injected Into… Not authorised
  2022-501644-15-00 Phase II Mild Cognitive Impairment due to Alzheimer's Disease Alzheim… Biogen Idec Research Limited
• A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Pati… Not authorised
  2022-502043-35-00 Phase III Advanced Biliary Tract Cancers AstraZeneca AB
• A clinical study of people with HIV‐1 who switch their treatment to a combination of doravirine and islatravir​​ Not authorised
  2022-502079-49-00 Phase III HIV-1 infection Merck Sharp & Dohme LLC
• A clinical study of people with HIV-1 who have not taken antiretroviral therapy, one group will start treatment with a combination of doravi… Not authorised
  2022-502099-22-00 Phase III HIV-1 Infection Merck Sharp & Dohme LLC
• A clinical study of people with HIV-1 who received prior treatment combination of doravirine and islatravir Not authorised
  2022-502126-40-00 Phase III HIV-1 infection Merck Sharp & Dohme LLC
• A randomised, controlled trial to investigate the effect of a four/six week intensified pharmacological treatment for schizophrenia, major d… Not authorised
  2022-502185-24-00 Phase III Schizophrenia, schizoaffective disorder, schizophreniform di… University Medical Center Utrecht
• MK-0616-013 Not authorised
  2022-502777-42-00 Phase III Hypercholesterolemia Merck Sharp & Dohme LLC
• FusionVAC22_01: DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocel… Not authorised
  2022-502869-17-00 Phase I tumor entities carrying the oncogenic driver fusion DNAJB1-P… Universitaetsklinikum Tuebingen
• A two part, randomized, double-blind, placebo-controlled, parallel group SAD and MD clinical study to evaluate the safety, tolerability and … Not authorised
  2022-503145-22-00 Phase I Pseudomonas colonization Charite Research Organisation GmbH

Showing 1–24 of 3,866 trials